IL315361A - Cancer vaccines and methods of use thereof - Google Patents

Cancer vaccines and methods of use thereof

Info

Publication number
IL315361A
IL315361A IL315361A IL31536124A IL315361A IL 315361 A IL315361 A IL 315361A IL 315361 A IL315361 A IL 315361A IL 31536124 A IL31536124 A IL 31536124A IL 315361 A IL315361 A IL 315361A
Authority
IL
Israel
Prior art keywords
hla
allele
cancer cell
gene
interleukin
Prior art date
Application number
IL315361A
Other languages
English (en)
Hebrew (he)
Inventor
William V Williams
Miguel Lopez-Lago
Markus Daniel Lacher
Original Assignee
Briacell Therapeutics Corp
William V Williams
Lopez Lago Miguel
Markus Daniel Lacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Briacell Therapeutics Corp, William V Williams, Lopez Lago Miguel, Markus Daniel Lacher filed Critical Briacell Therapeutics Corp
Publication of IL315361A publication Critical patent/IL315361A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL315361A 2022-03-03 2023-03-02 Cancer vaccines and methods of use thereof IL315361A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316251P 2022-03-03 2022-03-03
US202263415475P 2022-10-12 2022-10-12
PCT/US2023/014337 WO2023167973A1 (en) 2022-03-03 2023-03-02 Cancer vaccines and methods of use thereof

Publications (1)

Publication Number Publication Date
IL315361A true IL315361A (en) 2024-11-01

Family

ID=85772911

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315361A IL315361A (en) 2022-03-03 2023-03-02 Cancer vaccines and methods of use thereof

Country Status (8)

Country Link
US (1) US20250186568A1 (https=)
EP (1) EP4486371A1 (https=)
JP (1) JP2025507939A (https=)
CN (1) CN119053337A (https=)
AU (1) AU2023227477A1 (https=)
CA (1) CA3254024A1 (https=)
IL (1) IL315361A (https=)
WO (1) WO2023167973A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240156869A1 (en) * 2021-03-12 2024-05-16 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy
WO2025171109A1 (en) 2024-02-07 2025-08-14 Briacell Therapeutics Corp. Cancer vaccines expressing post-translational modified antigens and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
DE19832840C1 (de) * 1998-07-21 2000-06-08 Kerkmann Tucek Aida Mittel zur Immuntherapie von Tumorerkrankungen
US7807186B2 (en) * 2007-01-17 2010-10-05 University Of Maryland, Baltimore County Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
WO2017147600A1 (en) 2016-02-25 2017-08-31 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof

Also Published As

Publication number Publication date
AU2023227477A1 (en) 2024-09-19
US20250186568A1 (en) 2025-06-12
JP2025507939A (ja) 2025-03-21
EP4486371A1 (en) 2025-01-08
CN119053337A (zh) 2024-11-29
WO2023167973A1 (en) 2023-09-07
CA3254024A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
EP3885357B1 (en) Interleukin 21 protein (il21) mutant and use thereof
CN109152830B (zh) 用于免疫疗法的核/壳结构平台
TW202206453A (zh) 表現嵌合抗原受體之病毒特異性免疫細胞
KR20210122894A (ko) 다양한 암의 면역요법 치료에서의 사용을 위한 펩티드, 펩티드의 조합 및 골격
WO2016191305A1 (en) Btn3a ectodomain proteins and methods of use
IL292864A (en) New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
JP2022553192A (ja) 癌ワクチン
WO2021244486A1 (zh) 信号转换受体及其用途
US20250186568A1 (en) Cancer vaccines and methods of use thereof
US20220088162A1 (en) Heterologous Prime Boost Vaccine
CN113677362A (zh) 用于增强细胞免疫疗法的方法
CN111655278A (zh) 免疫治疗性癌症控制中的混合谱系激酶结构域样蛋白
US20240376429A1 (en) Virus-specific immune cells expressing chimeric antigen receptors
CN110115758B (zh) Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用
US20250302955A1 (en) Individualized cancer epitopes and methods of using the same
HK40117271A (zh) 癌症疫苗及其使用方法
WO2025171109A1 (en) Cancer vaccines expressing post-translational modified antigens and methods of use thereof
IL323635A (en) Methods for improving the immunogenicity of cellular vaccines
Wu Functions of cDC1 in Mediating CD4+ Help for CD8+ T cells
Wang et al. Rewiring dendritic cell function with CLEC9A and DEC205-based chimeric antigen receptors
JP2024538169A (ja) Ｎｄｃ８０抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
JP2025513890A (ja) 治療用ｔ細胞製品
JP2024526836A (ja) Ｆａｎｃｉ、ｒａｄ５１、およびｐｂｋ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法